Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Arpeggio Biosciences Inc. is managing 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This 1 pending office action is assigned to 1 distinct examiner, Rei Tsang Shiao, within 1 distinct art unit. This indicates a very focused prosecution landscape where only one matter is currently active.
Rei Tsang Shiao is the busiest examiner, responsible for 1 pending office action. This 1 pending office action represents the entire current workload for the company in the Biotechnology & Pharmaceuticals area. With only 1 distinct art unit and 1 distinct examiner involved, the company's current interaction with the patent office is limited to a single point of contact. The company must address the feedback from this 1 distinct examiner to resolve its 1 pending office action. This concentrated activity allows the company to focus its resources on a single regulatory challenge within the Biotechnology & Pharmaceuticals field.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SHIAO, REI TSANG | 1 | 79.9% | -33.5% |
| Art Unit | Apps |
|---|---|
| 1691 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18441446 | SMALL MOLECULE MODULATORS OF FERROPTOSIS | SHIAO, REI TSANG | 1691 | §112 | Non-Final OA | — | Pending | Feb 14, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialArpeggio Biosciences Inc. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Rei Tsang Shiao has the most, with 1 of Arpeggio Biosciences Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
